Shots:
- FDC has launched two variants of Favipiravir under the brand names PiFLU and Favenza to treat mild to moderate COVID-19 in India. The products will be available across the country
- Both the variant will be available at $0.74 (Rs. 55) /tablet. The DCGI had earlier approved the use of Favipiravir as an off-patent- oral antiviral drug that has shown clinical recovery in COVID-19 patients with mild to moderate symptoms
- Additionally- FDC has increased the production of Enerzal and Electral- as according to ASPEN guidelines- 03 liters of fluid intake in a day (60-20ml in every 30 min) helps in speedy recovery of people who are home quarantined
Ref: FDC | Image: Business Insider
Click here to read the full press release
Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at [email protected].
